Results 151 to 160 of about 12,771 (176)

[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].

Gan to kagaku ryoho. Cancer & chemotherapy, 2003
A 71-year-old man with chronic myelogenous leukemia received interferon therapy for 21 months, but did not have complete cytogenetic response. Imatinib was then added to the former therapy. Imatinib was prescribed for only 12 days and discontinued because of severe erythema.
Atsushi, Ajima, Naoya, Takayama, Yuichi, Hasegawa, Hiroshi, Kojima, Toshiro, Nagasawa   +4 more
openaire   +1 more source

Extramedullary BCR-ABL positive T-lymphoblastic leukemia in a patient with chronic myelogenous leukemia

Community Oncology, 2012
Mylene Go, Le Wang, JinMing Song, Rene Rubin   +3 more
openaire   +1 more source

Transgenic Mouse Models of BCR/ABL-Positive Chronic Myelogenous Leukemia: A Review

Current Genomics, 2005
openaire   +1 more source

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

Lancet, The, 2002
Nikolas Von Bubnoff Von Bubnoff, Folker Schneller   +1 more
exaly  

ABL-BCR expression in BCR-ABL-positive human leukemia cell lines

Leukemia Research, 1999
Cord Uphoff, Yoshinobu Matsuo, H G Drexler   +2 more
exaly  

Detection of bcr/abl fusion transcripts by semiquantitative multiplex RT-PCR combined with a colormetric assay in Ph positive leukemia

Cancer Letters, 1998
Shogo Banno, Taiji Kato, Atsushi Wakita   +2 more
exaly  

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Nature Medicine, 1996
Brian Druker, G M Segal, Elisabeth Buchdunger   +2 more
exaly  

Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemia

EMBO Molecular Medicine, 2010
Lothar Hennighausen, Veronika Sexl, Boris Kovacic   +2 more
exaly  

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Leukemia, 2013
Olaf Heidenreich, Simon Bomken, Oliver Ottmann   +2 more
exaly  

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells

Leukemia, 2001
M Porosnicu
exaly